James Plante is the Managing Partner and Founder of Thynk Capital. See contact routes.
James Plante is the Managing Partner and Founder of Thynk Capital, a privately-owned investment group he established with approximately 20 years of experience in early-stage technology and life science investing. His investment thesis targets early-stage companies in the Therapeutics, Healthcare, and Technology sectors, with a distinctive primary focus on longevity and defeating diseases of aging. While specific check sizes and lead/follow behavior are not publicly detailed, the firm aims to optimize early-stage company performance while delivering above-market returns to limited partners. Notable portfolio involvement includes Plante serving as a Seed Investor in IVIVA Medical Inc. and his leadership roles as CEO and Founder of Klotho Therapeutics and Intelligent Medicine Exchange (IMX). Plante’s distinctive point of view centers on developing human Klotho protein to address kidney diseases and aging challenges, reflecting his deep commitment to the longevity sector. He also founded the Foundation for Kidney Transplant Research and is a member of TIGER 21, further demonstrating his active contribution to kidney disease initiatives.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Las Vegas when building a target list.
Investors like James Plante · Full investor directory · Investor access · Company funding database